Medication-info.com Search Menu

Vueway: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Boxed warning
Strength:
485.1 mg/mL
Active ingredient:

Patient information: uses, side effects, how to take - Vueway

What is the most important information I should know about Vueway?

  • GBCAs like Vueway may cause serious side effects including death, coma, encephalopathy, and seizures when it is given intrathecally (injection given into the spinal canal). It is not known if Vueway is safe and effective with intrathecal use. Vueway is not approved for this use.
  • Vueway contains a metal called gadolinium. Small amounts of gadolinium can stay in your body including the brain, bones, skin and other parts of your body for a long time (several months to years).
  • It is not known how gadolinium may affect you, but so far, studies have not found harmful effects in patients with normal kidneys.
  • Rarely patients have reported pains, tiredness, and skin, muscle or bone ailments for a long time, but these symptoms have not been directly linked to gadolinium.
  • There are different GBCAs that can be used for your MRI exam. The amount of gadolinium that stays in the body is different for different gadolinium medicines. Gadolinium stays in the body more after gadodiamide than after gadoxetate disodium or gadobenate dimeglumine. Gadolinium stays in the body the least after, gadoterate meglumine, gadobutrol, gadoteridol, and gadopiclenol.
  • People who get many doses of gadolinium medicines, women who are pregnant and young children may be at increased risk from gadolinium staying in the body.
  • Some people with kidney problems who get gadolinium medicines can develop a condition with severe thickening of the skin, muscles and other organs in the body (nephrogenic systemic fibrosis). Your healthcare provider should screen you to see how well your kidneys are working before you receive Vueway.

What is Vueway?

  • Vueway is a prescription medicine called a gadolinium-based contrast agent (GBCA). Vueway, like other GBCAs, is injected into your vein and used with a magnetic resonance imaging (MRI) scanner.
  • An MRI exam with a GBCA, including Vueway, helps your healthcare provider to see problems better than an MRI exam without a GBCA.
  • Your healthcare provider has reviewed your medical records and has determined that you would benefit from using a GBCA with your MRI exam.

Do not receive Vueway if you have had a severe allergic reaction to Vueway.

Before receiving Vueway, tell your healthcare provider about all your medical conditions, including if you:

  • have had any MRI procedures in the past where you received a GBCA. Your healthcare provider may ask you for more information including the dates of these MRI procedures.
  • are pregnant or plan to become pregnant. It is not known if Vueway can harm your unborn baby. Talk to your healthcare provider about the possible risks to an unborn baby if a GBCA such as Vueway is received during pregnancy.

  • have kidney problems, diabetes, or high blood pressure.
  • have had an allergic reaction to dyes (contrast agents) including GBCAs.

What are possible side effects of Vueway?

  • See “What is the most important information I should know about Vueway?”
  • Allergic reactions. Vueway can cause allergic reactions that can sometimes be serious. Your healthcare provider will monitor you closely for symptoms of an allergic reaction.

The most common side effects of Vueway include: injection site pain, headache, nausea, injection site coldness, injection site warmth, dizziness, and localized swelling.

These are not all the possible side effects of Vueway.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective uses of Vueway.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your healthcare provider for information about Vueway that is written for health professionals.

What are the ingredients in Vueway?

Active ingredient: gadopiclenol

Inactive ingredients: tetraxetan; trometamol; hydrochloric acid or sodium hydroxide for pH adjustment; and water for injection

Vials manufactured by: BIPSO GmbH, 78224 Singen, Germany

Vials and pre-filled syringes manufactured by: Liebel-Flarsheim Company LLC, 8800 Durant Road, Raleigh, North Carolina (NC) 27616-3104, USA

Distributed by: Bracco Diagnostics Inc., Princeton, New Jersey, 08540, USA

For more information, go to www.imaging.bracco.com or call 800-257-5181.

Revised: February 2026

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: NDA 216986 · View the label on DailyMed

Revision date stated in the text: February 2026

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Vueway

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Boxed warning Yes – this drug has a boxed warning (also called a black box warning), the strongest warning of the FDA.
Active ingredient Gadopiclenol 485.1 mg/mL
Dosage form Injection
Route Intravenous
Marketing status listed in the FDA NDC Directory
Company (applicant) GUERBET
FDA approval NDA 216986New Drug Application (NDA) Approved September 21, 2022
Reference listed drug This is the reference listed drug (RLD) that generics are compared with.
Manufacturers 2 labelers list this drug on DailyMed
Packages (NDC)
Package
485.1 mg/mL – 30 ml in 1 vial, pharmacy bulk package / 25 in 1 case NDC 0270-7015-46
485.1 mg/mL – 50 ml in 1 vial, pharmacy bulk package / 25 in 1 case NDC 0270-7015-48
485.1 mg/mL – 100 ml in 1 vial, pharmacy bulk package / 1 in 1 carton / 6 in 1 case NDC 0270-7015-64
485.1 mg/mL – 30 ml in 1 vial, pharmacy bulk package / 10 in 1 case NDC 0270-7015-91
485.1 mg/mL – 50 ml in 1 vial, pharmacy bulk package / 10 in 1 case NDC 0270-7015-81
485.1 mg/mL – 100 ml in 1 vial, pharmacy bulk package / 10 in 1 case NDC 0270-7015-66
485.1 mg/mL – 30 ml in 1 vial / 10 in 1 case NDC 0270-7015-75
485.1 mg/mL – 50 ml in 1 vial / 10 in 1 case NDC 0270-7015-76
485.1 mg/mL – 100 ml in 1 vial / 10 in 1 case NDC 0270-7015-77
485.1 mg/mL – 3 ml in 1 vial, single-dose / 10 in 1 case NDC 0270-7020-38
485.1 mg/mL – 7.5 ml in 1 vial, single-dose / 10 in 1 case NDC 0270-7025-40
485.1 mg/mL – 10 ml in 1 vial, single-dose / 10 in 1 case NDC 0270-7030-42
Show more packages (1)+
485.1 mg/mL – 15 ml in 1 vial, single-dose / 10 in 1 case NDC 0270-7035-44

Source: FDA drug labeling via NLM DailyMed, data as of October 31, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.